nodes	percent_of_prediction	percent_of_DWPC	metapath
Conivaptan—Tolvaptan—Vismodegib—skin cancer	0.734	1	CrCrCtD
Conivaptan—CYP3A4—Imiquimod—skin cancer	0.0508	0.292	CbGbCtD
Conivaptan—CYP3A4—Temozolomide—skin cancer	0.0508	0.292	CbGbCtD
Conivaptan—CYP3A4—Vismodegib—skin cancer	0.0352	0.202	CbGbCtD
Conivaptan—CYP3A4—Vemurafenib—skin cancer	0.0279	0.16	CbGbCtD
Conivaptan—CYP3A4—Docetaxel—skin cancer	0.00956	0.0548	CbGbCtD
Conivaptan—Infusion site reaction—Docetaxel—skin cancer	0.00288	0.0368	CcSEcCtD
Conivaptan—AVPR2—Arf6 trafficking events—EXOC2—skin cancer	0.00205	0.151	CbGpPWpGaD
Conivaptan—Pharyngolaryngeal pain—Imiquimod—skin cancer	0.00166	0.0212	CcSEcCtD
Conivaptan—Laryngeal pain—Imiquimod—skin cancer	0.00164	0.021	CcSEcCtD
Conivaptan—Hyponatraemia—Vismodegib—skin cancer	0.00155	0.0198	CcSEcCtD
Conivaptan—Dehydration—Vismodegib—skin cancer	0.00143	0.0183	CcSEcCtD
Conivaptan—Hypokalaemia—Vismodegib—skin cancer	0.0014	0.0179	CcSEcCtD
Conivaptan—Hypomagnesaemia—Bleomycin—skin cancer	0.00125	0.016	CcSEcCtD
Conivaptan—Oral candidiasis—Temozolomide—skin cancer	0.00106	0.0135	CcSEcCtD
Conivaptan—Atrial fibrillation—Vemurafenib—skin cancer	0.001	0.0128	CcSEcCtD
Conivaptan—Malnutrition—Vismodegib—skin cancer	0.000928	0.0119	CcSEcCtD
Conivaptan—AVPR1A—Peptide GPCRs—MC1R—skin cancer	0.000883	0.0649	CbGpPWpGaD
Conivaptan—AVPR2—Peptide GPCRs—MC1R—skin cancer	0.000876	0.0644	CbGpPWpGaD
Conivaptan—Atrial fibrillation—Imiquimod—skin cancer	0.000857	0.0109	CcSEcCtD
Conivaptan—Cardiac failure—Imiquimod—skin cancer	0.000832	0.0106	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.000785	0.01	CcSEcCtD
Conivaptan—Nervous system disorder—Vismodegib—skin cancer	0.000743	0.00949	CcSEcCtD
Conivaptan—Skin disorder—Vismodegib—skin cancer	0.000736	0.0094	CcSEcCtD
Conivaptan—Infestation NOS—Vemurafenib—skin cancer	0.000734	0.00937	CcSEcCtD
Conivaptan—Infestation—Vemurafenib—skin cancer	0.000734	0.00937	CcSEcCtD
Conivaptan—Oral candidiasis—Docetaxel—skin cancer	0.000702	0.00896	CcSEcCtD
Conivaptan—Phlebitis—Bleomycin—skin cancer	0.00067	0.00855	CcSEcCtD
Conivaptan—Pharyngolaryngeal pain—Docetaxel—skin cancer	0.00066	0.00843	CcSEcCtD
Conivaptan—Laryngeal pain—Docetaxel—skin cancer	0.000654	0.00835	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Vismodegib—skin cancer	0.000654	0.00835	CcSEcCtD
Conivaptan—Oedema peripheral—Vemurafenib—skin cancer	0.000649	0.00829	CcSEcCtD
Conivaptan—Constipation—Vismodegib—skin cancer	0.000648	0.00827	CcSEcCtD
Conivaptan—Pain—Vismodegib—skin cancer	0.000648	0.00827	CcSEcCtD
Conivaptan—Sepsis—Dactinomycin—skin cancer	0.000643	0.00822	CcSEcCtD
Conivaptan—Candida infection—Temozolomide—skin cancer	0.00064	0.00817	CcSEcCtD
Conivaptan—Infestation NOS—Imiquimod—skin cancer	0.000626	0.00799	CcSEcCtD
Conivaptan—Infestation—Imiquimod—skin cancer	0.000626	0.00799	CcSEcCtD
Conivaptan—Phlebitis—Dactinomycin—skin cancer	0.000625	0.00798	CcSEcCtD
Conivaptan—Cardiac disorder—Vemurafenib—skin cancer	0.000611	0.00781	CcSEcCtD
Conivaptan—Urinary tract infection—Imiquimod—skin cancer	0.000608	0.00777	CcSEcCtD
Conivaptan—Angiopathy—Vemurafenib—skin cancer	0.000598	0.00763	CcSEcCtD
Conivaptan—Mediastinal disorder—Vemurafenib—skin cancer	0.000594	0.00758	CcSEcCtD
Conivaptan—AVPR2—G alpha (s) signalling events—MC1R—skin cancer	0.00058	0.0426	CbGpPWpGaD
Conivaptan—Malnutrition—Vemurafenib—skin cancer	0.000573	0.00732	CcSEcCtD
Conivaptan—Erythema—Vemurafenib—skin cancer	0.000573	0.00732	CcSEcCtD
Conivaptan—Urinary tract disorder—Imiquimod—skin cancer	0.000555	0.00709	CcSEcCtD
Conivaptan—Urethral disorder—Imiquimod—skin cancer	0.000551	0.00703	CcSEcCtD
Conivaptan—Sepsis—Fluorouracil—skin cancer	0.000536	0.00685	CcSEcCtD
Conivaptan—Pruritus—Vismodegib—skin cancer	0.000536	0.00685	CcSEcCtD
Conivaptan—Diarrhoea—Vismodegib—skin cancer	0.000518	0.00662	CcSEcCtD
Conivaptan—Thirst—Temozolomide—skin cancer	0.000511	0.00653	CcSEcCtD
Conivaptan—Angiopathy—Imiquimod—skin cancer	0.00051	0.00651	CcSEcCtD
Conivaptan—Mediastinal disorder—Imiquimod—skin cancer	0.000506	0.00647	CcSEcCtD
Conivaptan—Mental disorder—Imiquimod—skin cancer	0.000492	0.00629	CcSEcCtD
Conivaptan—Erythema—Imiquimod—skin cancer	0.000489	0.00625	CcSEcCtD
Conivaptan—Malnutrition—Imiquimod—skin cancer	0.000489	0.00625	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000485	0.00619	CcSEcCtD
Conivaptan—Vomiting—Vismodegib—skin cancer	0.000482	0.00615	CcSEcCtD
Conivaptan—Infection—Vemurafenib—skin cancer	0.000465	0.00594	CcSEcCtD
Conivaptan—Cardiac failure—Fluorouracil—skin cancer	0.000459	0.00587	CcSEcCtD
Conivaptan—Nervous system disorder—Vemurafenib—skin cancer	0.000459	0.00586	CcSEcCtD
Conivaptan—Skin disorder—Vemurafenib—skin cancer	0.000455	0.00581	CcSEcCtD
Conivaptan—Dehydration—Temozolomide—skin cancer	0.000453	0.00578	CcSEcCtD
Conivaptan—Nausea—Vismodegib—skin cancer	0.00045	0.00575	CcSEcCtD
Conivaptan—Pneumonia—Bleomycin—skin cancer	0.000447	0.00571	CcSEcCtD
Conivaptan—Hypokalaemia—Temozolomide—skin cancer	0.000443	0.00566	CcSEcCtD
Conivaptan—Hypotension—Vemurafenib—skin cancer	0.000437	0.00559	CcSEcCtD
Conivaptan—Candida infection—Docetaxel—skin cancer	0.000426	0.00544	CcSEcCtD
Conivaptan—Haematuria—Bleomycin—skin cancer	0.000424	0.00541	CcSEcCtD
Conivaptan—Hypertension—Imiquimod—skin cancer	0.000422	0.00539	CcSEcCtD
Conivaptan—Pneumonia—Dactinomycin—skin cancer	0.000417	0.00533	CcSEcCtD
Conivaptan—AVPR1A—Peptide ligand-binding receptors—MC1R—skin cancer	0.000415	0.0305	CbGpPWpGaD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000413	0.00528	CcSEcCtD
Conivaptan—AVPR2—Peptide ligand-binding receptors—MC1R—skin cancer	0.000412	0.0303	CbGpPWpGaD
Conivaptan—Dry mouth—Imiquimod—skin cancer	0.000407	0.0052	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000404	0.00516	CcSEcCtD
Conivaptan—Constipation—Vemurafenib—skin cancer	0.0004	0.00511	CcSEcCtD
Conivaptan—Infection—Imiquimod—skin cancer	0.000397	0.00506	CcSEcCtD
Conivaptan—Nervous system disorder—Imiquimod—skin cancer	0.000391	0.005	CcSEcCtD
Conivaptan—Pollakiuria—Temozolomide—skin cancer	0.000389	0.00496	CcSEcCtD
Conivaptan—Skin disorder—Imiquimod—skin cancer	0.000388	0.00495	CcSEcCtD
Conivaptan—Sepsis—Docetaxel—skin cancer	0.000387	0.00494	CcSEcCtD
Conivaptan—AVPR2—G alpha (s) signalling events—PTGER4—skin cancer	0.000381	0.028	CbGpPWpGaD
Conivaptan—Hyperglycaemia—Temozolomide—skin cancer	0.000379	0.00485	CcSEcCtD
Conivaptan—Pneumonia—Temozolomide—skin cancer	0.000377	0.00482	CcSEcCtD
Conivaptan—Phlebitis—Docetaxel—skin cancer	0.000376	0.0048	CcSEcCtD
Conivaptan—Infestation NOS—Temozolomide—skin cancer	0.000375	0.00479	CcSEcCtD
Conivaptan—Infestation—Temozolomide—skin cancer	0.000375	0.00479	CcSEcCtD
Conivaptan—Body temperature increased—Vemurafenib—skin cancer	0.00037	0.00473	CcSEcCtD
Conivaptan—Urinary tract infection—Temozolomide—skin cancer	0.000365	0.00466	CcSEcCtD
Conivaptan—Insomnia—Imiquimod—skin cancer	0.000361	0.00461	CcSEcCtD
Conivaptan—Pneumonia—Fluorouracil—skin cancer	0.000348	0.00444	CcSEcCtD
Conivaptan—Erythema—Bleomycin—skin cancer	0.000347	0.00444	CcSEcCtD
Conivaptan—Infestation—Fluorouracil—skin cancer	0.000346	0.00441	CcSEcCtD
Conivaptan—Infestation NOS—Fluorouracil—skin cancer	0.000346	0.00441	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Imiquimod—skin cancer	0.000345	0.0044	CcSEcCtD
Conivaptan—Atrial fibrillation—Docetaxel—skin cancer	0.000341	0.00436	CcSEcCtD
Conivaptan—Pain—Imiquimod—skin cancer	0.000341	0.00436	CcSEcCtD
Conivaptan—Urinary tract infection—Fluorouracil—skin cancer	0.000336	0.00429	CcSEcCtD
Conivaptan—Urinary tract disorder—Temozolomide—skin cancer	0.000332	0.00425	CcSEcCtD
Conivaptan—Oedema peripheral—Temozolomide—skin cancer	0.000332	0.00424	CcSEcCtD
Conivaptan—Cardiac failure—Docetaxel—skin cancer	0.000332	0.00424	CcSEcCtD
Conivaptan—Pruritus—Vemurafenib—skin cancer	0.000331	0.00423	CcSEcCtD
Conivaptan—Urethral disorder—Temozolomide—skin cancer	0.00033	0.00421	CcSEcCtD
Conivaptan—Feeling abnormal—Imiquimod—skin cancer	0.000329	0.0042	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000325	0.0239	CbGpPWpGaD
Conivaptan—Hyponatraemia—Docetaxel—skin cancer	0.000325	0.00415	CcSEcCtD
Conivaptan—Erythema—Dactinomycin—skin cancer	0.000324	0.00414	CcSEcCtD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000323	0.0237	CbGpPWpGaD
Conivaptan—Anaemia—Bleomycin—skin cancer	0.000321	0.0041	CcSEcCtD
Conivaptan—Diarrhoea—Vemurafenib—skin cancer	0.00032	0.00409	CcSEcCtD
Conivaptan—Body temperature increased—Imiquimod—skin cancer	0.000316	0.00403	CcSEcCtD
Conivaptan—Cardiac disorder—Temozolomide—skin cancer	0.000312	0.00399	CcSEcCtD
Conivaptan—Angiopathy—Temozolomide—skin cancer	0.000305	0.0039	CcSEcCtD
Conivaptan—Mediastinal disorder—Temozolomide—skin cancer	0.000303	0.00388	CcSEcCtD
Conivaptan—Dehydration—Docetaxel—skin cancer	0.000301	0.00384	CcSEcCtD
Conivaptan—Anaemia—Dactinomycin—skin cancer	0.000299	0.00383	CcSEcCtD
Conivaptan—Vomiting—Vemurafenib—skin cancer	0.000298	0.0038	CcSEcCtD
Conivaptan—Orthostatic hypotension—Docetaxel—skin cancer	0.000296	0.00378	CcSEcCtD
Conivaptan—Mental disorder—Temozolomide—skin cancer	0.000295	0.00377	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—PTCH2—skin cancer	0.000293	0.0215	CbGpPWpGaD
Conivaptan—Headache—Vemurafenib—skin cancer	0.000293	0.00374	CcSEcCtD
Conivaptan—Malnutrition—Temozolomide—skin cancer	0.000293	0.00374	CcSEcCtD
Conivaptan—Erythema—Temozolomide—skin cancer	0.000293	0.00374	CcSEcCtD
Conivaptan—AVPR2—GPCR ligand binding—PTCH2—skin cancer	0.000291	0.0214	CbGpPWpGaD
Conivaptan—Confusional state—Bleomycin—skin cancer	0.000286	0.00365	CcSEcCtD
Conivaptan—Pruritus—Imiquimod—skin cancer	0.000282	0.00361	CcSEcCtD
Conivaptan—Infection—Bleomycin—skin cancer	0.000282	0.0036	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000278	0.0205	CbGpPWpGaD
Conivaptan—Nausea—Vemurafenib—skin cancer	0.000278	0.00355	CcSEcCtD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000276	0.0203	CbGpPWpGaD
Conivaptan—Diarrhoea—Imiquimod—skin cancer	0.000273	0.00349	CcSEcCtD
Conivaptan—Anaemia—Temozolomide—skin cancer	0.000271	0.00346	CcSEcCtD
Conivaptan—Erythema—Fluorouracil—skin cancer	0.00027	0.00345	CcSEcCtD
Conivaptan—Hypotension—Bleomycin—skin cancer	0.000265	0.00338	CcSEcCtD
Conivaptan—Infection—Dactinomycin—skin cancer	0.000263	0.00336	CcSEcCtD
Conivaptan—Vomiting—Imiquimod—skin cancer	0.000254	0.00324	CcSEcCtD
Conivaptan—Hypertension—Temozolomide—skin cancer	0.000253	0.00323	CcSEcCtD
Conivaptan—Pneumonia—Docetaxel—skin cancer	0.000251	0.0032	CcSEcCtD
Conivaptan—Headache—Imiquimod—skin cancer	0.00025	0.00319	CcSEcCtD
Conivaptan—Anaemia—Fluorouracil—skin cancer	0.00025	0.00319	CcSEcCtD
Conivaptan—Infestation—Docetaxel—skin cancer	0.000249	0.00319	CcSEcCtD
Conivaptan—Infestation NOS—Docetaxel—skin cancer	0.000249	0.00319	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000248	0.00316	CcSEcCtD
Conivaptan—Dry mouth—Temozolomide—skin cancer	0.000244	0.00312	CcSEcCtD
Conivaptan—Pain—Bleomycin—skin cancer	0.000242	0.0031	CcSEcCtD
Conivaptan—Confusional state—Temozolomide—skin cancer	0.000241	0.00308	CcSEcCtD
Conivaptan—Infection—Temozolomide—skin cancer	0.000238	0.00303	CcSEcCtD
Conivaptan—Nausea—Imiquimod—skin cancer	0.000237	0.00303	CcSEcCtD
Conivaptan—Nervous system disorder—Temozolomide—skin cancer	0.000235	0.003	CcSEcCtD
Conivaptan—Feeling abnormal—Bleomycin—skin cancer	0.000234	0.00298	CcSEcCtD
Conivaptan—Skin disorder—Temozolomide—skin cancer	0.000232	0.00297	CcSEcCtD
Conivaptan—Pain—Dactinomycin—skin cancer	0.000226	0.00289	CcSEcCtD
Conivaptan—Body temperature increased—Bleomycin—skin cancer	0.000224	0.00286	CcSEcCtD
Conivaptan—Confusional state—Fluorouracil—skin cancer	0.000222	0.00284	CcSEcCtD
Conivaptan—Urinary tract disorder—Docetaxel—skin cancer	0.000221	0.00282	CcSEcCtD
Conivaptan—Oedema peripheral—Docetaxel—skin cancer	0.000221	0.00282	CcSEcCtD
Conivaptan—Urethral disorder—Docetaxel—skin cancer	0.000219	0.0028	CcSEcCtD
Conivaptan—Infection—Fluorouracil—skin cancer	0.000219	0.0028	CcSEcCtD
Conivaptan—Feeling abnormal—Dactinomycin—skin cancer	0.000218	0.00278	CcSEcCtD
Conivaptan—Insomnia—Temozolomide—skin cancer	0.000216	0.00276	CcSEcCtD
Conivaptan—Nervous system disorder—Fluorouracil—skin cancer	0.000216	0.00276	CcSEcCtD
Conivaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000214	0.0157	CbGpPWpGaD
Conivaptan—AVPR2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000212	0.0156	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—MC1R—skin cancer	0.000212	0.0156	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—MC1R—skin cancer	0.00021	0.0155	CbGpPWpGaD
Conivaptan—Body temperature increased—Dactinomycin—skin cancer	0.000209	0.00267	CcSEcCtD
Conivaptan—Cardiac disorder—Docetaxel—skin cancer	0.000208	0.00265	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Temozolomide—skin cancer	0.000206	0.00264	CcSEcCtD
Conivaptan—Hypotension—Fluorouracil—skin cancer	0.000206	0.00263	CcSEcCtD
Conivaptan—Pain—Temozolomide—skin cancer	0.000205	0.00261	CcSEcCtD
Conivaptan—Constipation—Temozolomide—skin cancer	0.000205	0.00261	CcSEcCtD
Conivaptan—Angiopathy—Docetaxel—skin cancer	0.000203	0.00259	CcSEcCtD
Conivaptan—Mediastinal disorder—Docetaxel—skin cancer	0.000202	0.00258	CcSEcCtD
Conivaptan—AVPR2—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000201	0.0148	CbGpPWpGaD
Conivaptan—Pruritus—Bleomycin—skin cancer	0.000201	0.00256	CcSEcCtD
Conivaptan—Insomnia—Fluorouracil—skin cancer	0.000199	0.00255	CcSEcCtD
Conivaptan—Feeling abnormal—Temozolomide—skin cancer	0.000197	0.00252	CcSEcCtD
Conivaptan—Mental disorder—Docetaxel—skin cancer	0.000196	0.00251	CcSEcCtD
Conivaptan—Erythema—Docetaxel—skin cancer	0.000195	0.00249	CcSEcCtD
Conivaptan—Malnutrition—Docetaxel—skin cancer	0.000195	0.00249	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00019	0.00243	CcSEcCtD
Conivaptan—Body temperature increased—Temozolomide—skin cancer	0.000189	0.00241	CcSEcCtD
Conivaptan—Pain—Fluorouracil—skin cancer	0.000188	0.00241	CcSEcCtD
Conivaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000183	0.0135	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—RHOU—skin cancer	0.000182	0.0134	CbGpPWpGaD
Conivaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000182	0.0134	CbGpPWpGaD
Conivaptan—Feeling abnormal—Fluorouracil—skin cancer	0.000182	0.00232	CcSEcCtD
Conivaptan—Diarrhoea—Dactinomycin—skin cancer	0.000181	0.00231	CcSEcCtD
Conivaptan—AVPR2—Signaling Pathways—RHOU—skin cancer	0.000181	0.0133	CbGpPWpGaD
Conivaptan—Vomiting—Bleomycin—skin cancer	0.00018	0.0023	CcSEcCtD
Conivaptan—Anaemia—Docetaxel—skin cancer	0.00018	0.0023	CcSEcCtD
Conivaptan—Body temperature increased—Fluorouracil—skin cancer	0.000174	0.00223	CcSEcCtD
Conivaptan—Pruritus—Temozolomide—skin cancer	0.000169	0.00216	CcSEcCtD
Conivaptan—Nausea—Bleomycin—skin cancer	0.000168	0.00215	CcSEcCtD
Conivaptan—Hypertension—Docetaxel—skin cancer	0.000168	0.00215	CcSEcCtD
Conivaptan—Vomiting—Dactinomycin—skin cancer	0.000168	0.00215	CcSEcCtD
Conivaptan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000165	0.0021	CcSEcCtD
Conivaptan—Diarrhoea—Temozolomide—skin cancer	0.000164	0.00209	CcSEcCtD
Conivaptan—Dry mouth—Docetaxel—skin cancer	0.000162	0.00207	CcSEcCtD
Conivaptan—Confusional state—Docetaxel—skin cancer	0.00016	0.00205	CcSEcCtD
Conivaptan—Infection—Docetaxel—skin cancer	0.000158	0.00202	CcSEcCtD
Conivaptan—Nausea—Dactinomycin—skin cancer	0.000157	0.00201	CcSEcCtD
Conivaptan—Nervous system disorder—Docetaxel—skin cancer	0.000156	0.00199	CcSEcCtD
Conivaptan—Pruritus—Fluorouracil—skin cancer	0.000156	0.00199	CcSEcCtD
Conivaptan—Skin disorder—Docetaxel—skin cancer	0.000154	0.00197	CcSEcCtD
Conivaptan—Vomiting—Temozolomide—skin cancer	0.000152	0.00194	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—SHH—skin cancer	0.000151	0.0111	CbGpPWpGaD
Conivaptan—Diarrhoea—Fluorouracil—skin cancer	0.000151	0.00193	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—PTCH2—skin cancer	0.00015	0.0111	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—SHH—skin cancer	0.00015	0.011	CbGpPWpGaD
Conivaptan—Headache—Temozolomide—skin cancer	0.00015	0.00191	CcSEcCtD
Conivaptan—AVPR2—Signaling by GPCR—PTCH2—skin cancer	0.000149	0.011	CbGpPWpGaD
Conivaptan—Hypotension—Docetaxel—skin cancer	0.000149	0.0019	CcSEcCtD
Conivaptan—Insomnia—Docetaxel—skin cancer	0.000144	0.00184	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—PTCH1—skin cancer	0.000143	0.0105	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR ligand binding—SMO—skin cancer	0.000143	0.0105	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—SMO—skin cancer	0.000142	0.0104	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—PTCH1—skin cancer	0.000142	0.0104	CbGpPWpGaD
Conivaptan—Nausea—Temozolomide—skin cancer	0.000142	0.00181	CcSEcCtD
Conivaptan—Vomiting—Fluorouracil—skin cancer	0.00014	0.00179	CcSEcCtD
Conivaptan—AVPR1A—GPCR ligand binding—PTGER4—skin cancer	0.000139	0.0102	CbGpPWpGaD
Conivaptan—AVPR2—GPCR ligand binding—PTGER4—skin cancer	0.000138	0.0102	CbGpPWpGaD
Conivaptan—Headache—Fluorouracil—skin cancer	0.000138	0.00176	CcSEcCtD
Conivaptan—Gastrointestinal disorder—Docetaxel—skin cancer	0.000137	0.00175	CcSEcCtD
Conivaptan—Constipation—Docetaxel—skin cancer	0.000136	0.00174	CcSEcCtD
Conivaptan—Pain—Docetaxel—skin cancer	0.000136	0.00174	CcSEcCtD
Conivaptan—Feeling abnormal—Docetaxel—skin cancer	0.000131	0.00167	CcSEcCtD
Conivaptan—Nausea—Fluorouracil—skin cancer	0.000131	0.00167	CcSEcCtD
Conivaptan—Body temperature increased—Docetaxel—skin cancer	0.000126	0.00161	CcSEcCtD
Conivaptan—AVPR1A—GPCR downstream signaling—MC1R—skin cancer	0.00012	0.0088	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—MC1R—skin cancer	0.000119	0.00874	CbGpPWpGaD
Conivaptan—Pruritus—Docetaxel—skin cancer	0.000113	0.00144	CcSEcCtD
Conivaptan—Diarrhoea—Docetaxel—skin cancer	0.000109	0.00139	CcSEcCtD
Conivaptan—AVPR1A—Signaling by GPCR—MC1R—skin cancer	0.000109	0.00799	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—MC1R—skin cancer	0.000108	0.00794	CbGpPWpGaD
Conivaptan—Vomiting—Docetaxel—skin cancer	0.000101	0.00129	CcSEcCtD
Conivaptan—Headache—Docetaxel—skin cancer	9.96e-05	0.00127	CcSEcCtD
Conivaptan—Nausea—Docetaxel—skin cancer	9.45e-05	0.00121	CcSEcCtD
Conivaptan—AVPR1A—Signaling Pathways—PTCH2—skin cancer	8.89e-05	0.00653	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTCH2—skin cancer	8.83e-05	0.00649	CbGpPWpGaD
Conivaptan—AVPR1A—GPCR downstream signaling—PTGER4—skin cancer	7.88e-05	0.00579	CbGpPWpGaD
Conivaptan—AVPR2—GPCR downstream signaling—PTGER4—skin cancer	7.82e-05	0.00575	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—SHH—skin cancer	7.75e-05	0.0057	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—SHH—skin cancer	7.7e-05	0.00566	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PTCH1—skin cancer	7.35e-05	0.0054	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—SMO—skin cancer	7.35e-05	0.0054	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—SMO—skin cancer	7.3e-05	0.00536	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PTCH1—skin cancer	7.3e-05	0.00536	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	7.26e-05	0.00533	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—PTGER4—skin cancer	7.15e-05	0.00526	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—PTGER4—skin cancer	7.1e-05	0.00522	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GLI2—skin cancer	6.74e-05	0.00495	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GLI2—skin cancer	6.69e-05	0.00492	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—MC1R—skin cancer	6.43e-05	0.00472	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—MC1R—skin cancer	6.38e-05	0.00469	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—GLI1—skin cancer	6.33e-05	0.00465	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—GLI1—skin cancer	6.29e-05	0.00462	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	6.25e-05	0.00459	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SUFU—skin cancer	6.01e-05	0.00441	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SUFU—skin cancer	5.96e-05	0.00438	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	5.31e-05	0.0039	CbGpPWpGaD
Conivaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	5.08e-05	0.00374	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SHH—skin cancer	4.58e-05	0.00337	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—RASA1—skin cancer	4.55e-05	0.00334	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SHH—skin cancer	4.55e-05	0.00334	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—RASA1—skin cancer	4.52e-05	0.00332	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTCH1—skin cancer	4.34e-05	0.00319	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—SMO—skin cancer	4.34e-05	0.00319	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTCH1—skin cancer	4.31e-05	0.00317	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—SMO—skin cancer	4.31e-05	0.00317	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—PTGER4—skin cancer	4.23e-05	0.00311	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—PTGER4—skin cancer	4.2e-05	0.00308	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—FOXO4—skin cancer	3.73e-05	0.00274	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—FOXO4—skin cancer	3.71e-05	0.00272	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TERT—skin cancer	2.49e-05	0.00183	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TERT—skin cancer	2.48e-05	0.00182	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—NRAS—skin cancer	2.1e-05	0.00154	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—NRAS—skin cancer	2.09e-05	0.00153	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—BRAF—skin cancer	1.97e-05	0.00145	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—BRAF—skin cancer	1.96e-05	0.00144	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—KRAS—skin cancer	1.81e-05	0.00133	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—KRAS—skin cancer	1.8e-05	0.00132	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—HRAS—skin cancer	1.54e-05	0.00113	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—HRAS—skin cancer	1.53e-05	0.00112	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling by GPCR—IL6—skin cancer	1.47e-05	0.00108	CbGpPWpGaD
Conivaptan—AVPR2—Signaling by GPCR—IL6—skin cancer	1.46e-05	0.00107	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—NRAS—skin cancer	1.24e-05	0.000912	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—NRAS—skin cancer	1.23e-05	0.000905	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PLIN2—skin cancer	1.16e-05	0.000856	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—KRAS—skin cancer	1.07e-05	0.000785	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—KRAS—skin cancer	1.06e-05	0.000779	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—TP53—skin cancer	9.49e-06	0.000698	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—TP53—skin cancer	9.43e-06	0.000693	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—CSPG4—skin cancer	9.39e-06	0.00069	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—HRAS—skin cancer	9.08e-06	0.000667	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—HRAS—skin cancer	9.01e-06	0.000662	CbGpPWpGaD
Conivaptan—AVPR1A—Signaling Pathways—IL6—skin cancer	8.69e-06	0.000639	CbGpPWpGaD
Conivaptan—AVPR2—Signaling Pathways—IL6—skin cancer	8.63e-06	0.000634	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ENO2—skin cancer	6.38e-06	0.000469	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—ERCC2—skin cancer	3.71e-06	0.000272	CbGpPWpGaD
Conivaptan—CYP3A4—Metabolism—PTGS2—skin cancer	2.22e-06	0.000163	CbGpPWpGaD
